Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corevia is a nutritional supplement developed by Blue Heron Pharmaceuticals, primarily composed of Huperzine A, a sesquiterpene alkaloid extracted from the club moss *Huperzia serrata*. It functions as a potent, reversible, and selective inhibitor of acetylcholinesterase (AChE), the enzyme responsible for degrading the neurotransmitter acetylcholine. By increasing acetylcholine levels in the brain, Corevia is intended to support cognitive functions such as memory, focus, and learning. It is marketed as a high-purity botanical extract for neuroprotection and cognitive enhancement, specifically targeting the maintenance of healthy brain function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Corevia.